Search research articles
Contact Us
Filters
Showing results (11-20 of 48) with videos related to
Page
of 5
Sort By:
Expert Opinion on Investigational Drugs
|
August 25, 2012
Discontinued drugs 2011: endocrine and metabolic
Jerry R Colca
Combinatorial Chemistry & High Throughput Screening
|
December 8, 2004
Photo-affinity labeling strategies in identifying the protein ligands of bioactive small molecules: examples of targeted synthesis of drug analog photoprobes
Jerry R Colca, George G Harrigan
Expert Opinion on Investigational Drugs
|
February 6, 2025
Metabolic dysfunction and insulin sensitizers in acute and chronic disease
Jerry R Colca, Kyle S McCommis
Advances in Pharmacology (San Diego, Calif.)
|
July 31, 2012
Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease
Jerry R Colca, Douglas L Feinstein
Advances in Pharmacology (San Diego, Calif.)
|
March 17, 2010
Current and emerging strategies for treating dyslipidemia and macrovascular disease
Jerry R Colca, Rolf F Kletzien
Molecular Metabolism
|
December 5, 2021
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease
Jerry R Colca, Philipp E Scherer
Frontiers in Molecular Biosciences
|
July 5, 2022
Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches
Jerry R Colca, Brian N Finck
Expert Opinion on Investigational Drugs
|
March 1, 2006
What has prevented the expansion of insulin sensitisers?
Jerry R Colca, Rolf F Kletzien
Expert Opinion on Investigational Drugs
|
June 29, 2018
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Jerry R Colca, William G McDonald, Wade J Adams
Hepatology (Baltimore, Md.)
|
March 21, 2017
Reply
Kyle S McCommis, Jerry R Colca, Brian N Finck
Page
of 5
Search research articles
Search
Showing results (11-20 of 48) with videos related to
Sort By:
Page
of 5
Expert Opinion on Investigational Drugs
|
August 25, 2012
Discontinued drugs 2011: endocrine and metabolic
Jerry R Colca
Combinatorial Chemistry & High Throughput Screening
|
December 8, 2004
Photo-affinity labeling strategies in identifying the protein ligands of bioactive small molecules: examples of targeted synthesis of drug analog photoprobes
Jerry R Colca, George G Harrigan
Expert Opinion on Investigational Drugs
|
February 6, 2025
Metabolic dysfunction and insulin sensitizers in acute and chronic disease
Jerry R Colca, Kyle S McCommis
Advances in Pharmacology (San Diego, Calif.)
|
July 31, 2012
Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease
Jerry R Colca, Douglas L Feinstein
Advances in Pharmacology (San Diego, Calif.)
|
March 17, 2010
Current and emerging strategies for treating dyslipidemia and macrovascular disease
Jerry R Colca, Rolf F Kletzien
Molecular Metabolism
|
December 5, 2021
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease
Jerry R Colca, Philipp E Scherer
Frontiers in Molecular Biosciences
|
July 5, 2022
Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches
Jerry R Colca, Brian N Finck
Expert Opinion on Investigational Drugs
|
March 1, 2006
What has prevented the expansion of insulin sensitisers?
Jerry R Colca, Rolf F Kletzien
Expert Opinion on Investigational Drugs
|
June 29, 2018
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Jerry R Colca, William G McDonald, Wade J Adams
Hepatology (Baltimore, Md.)
|
March 21, 2017
Reply
Kyle S McCommis, Jerry R Colca, Brian N Finck
Page
of 5